HLA-C and intrahepatic cholangiocarcinoma: In addition, we also defined 20 FMGs in ICC samples from the Shanghai cohort, including TP53 (40%), KRAS (17%), C16orf3 (16%), HLA-A (15%), TTN (15%), FAM230A (13%), HLA-C (13%), MUC16 (13%), AHNAK2 (12%), and CTD-3193O13.9 (11%) (Figure 1C).